Cargando…
Validation of a 3-h Sampling Interval to Assess Variability in Cytochrome P450 3A Phenotype and the Impact of Induction and Mechanism-Based Inhibition Using Midazolam as a Probe Substrate
Background: Drug probe phenotyping is used extensively in academic and industry research to evaluate cytochrome P450 (CYP) phenotype in order to account for sources of between- and within- subject variability in metabolic clearance. In terms of application, CYP3A is the most important drug metaboliz...
Autores principales: | van Dyk, Madelé, Kapetas, Asha J., Hopkins, Ashley M., Rodrigues, A. David, Vourvahis, Manoli, Sorich, Michael J., Rowland, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777419/ https://www.ncbi.nlm.nih.gov/pubmed/31611799 http://dx.doi.org/10.3389/fphar.2019.01120 |
Ejemplares similares
-
Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants
por: Hoch, Matthias, et al.
Publicado: (2022) -
Probing Steroidal Substrate Specificity of Cytochrome P450 BM3 Variants
por: Liu, Xing, et al.
Publicado: (2016) -
Secukinumab Treatment Does Not Alter the Pharmacokinetics of the Cytochrome P450 3A4 Substrate Midazolam in Patients With Moderate to Severe Psoriasis
por: Bruin, Gerard, et al.
Publicado: (2019) -
Evaluation of Luminogenic Substrates as Probe Substrates for Bacterial Cytochrome P450 Enzymes: Application to Mycobacterium tuberculosis
por: Ortega Ugalde, Sandra, et al.
Publicado: (2019) -
Homotropic Cooperativity of Midazolam Metabolism by
Cytochrome P450 3A4: Insight from Computational Studies
por: Li, Junhao, et al.
Publicado: (2021)